Gürsoy P. Avascular necrosis during alectinib treatment: Case report.
J Oncol Pharm Pract 2023;
29:242-245. [PMID:
35635227 DOI:
10.1177/10781552221102370]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
CASE REPORT
We present our patient who used alectinib due to anaplastic lymphoma kinase positivity and developed avascular necrosis in the femoral head.
MANAGEMENT AND OUTCOME
In our patient who had been taking alectinib for a long time due to anaplastic lymphoma kinase positivity, avascular necrosis of the femoral head was detected as a result of the examination performed due to hip pain. Due to the responsıbılıty of the disease, her treatment contınued by making profit and loss account.
DISCUSSION
Femoral head avascular necrosis can be seen with tyrosine kinase inhibitors, although it is very rare. This is the case in the literature to develop avascular necrosis due to alectinib. We think that femoral head necrosis may develop in the patient group using alectinib and care should be taken in this regard.
Collapse